Market Value957,232,000
Total Holdings51
File Date2020-05-15
Original Filing (Click here)

All hedge funds or institutions that manage over $100M are required by the SEC to file quarterly reports on their holdings. These reports are called 13F reports. However, the filings are required the following quarter from the reporting period, which means that by the time the filing is made (and we see them), the information could be five months old.

For funds with long term positions that make few trades, the holdings might closely resemble their current holdings, even after several months. However, for funds that have high turnover, the holdings data we see might differ significantly from their current holdings. Institutions are required to report CALL and PUT options, and those positions are identified in the table. However, they are not required to report short positions.

Click the link icon to see the full transaction history.

Upgrade to unlock premium data and export to Excel .

Security Imputed
Share Price
Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
(USD x1000)
Current Value
(USD x1000)
Change
(Percent)
CRVS / Corvus Pharmaceuticals, Inc.
VINC / Vincerx Pharma, Inc.
PRTA / Prothena Corporation plc
XCUR / Exicure, Inc.
VCEL / Vericel Corporation
BMRN / BioMarin Pharmaceutical Inc. Call
ZYME / Zymeworks Inc.
EOLS / Evolus, Inc.
RUBY / Rubius Therapeutics, Inc.
PBYI / Puma Biotechnology, Inc.
VIR / Vir Biotechnology, Inc.
110122157 / Bristol Meyers Squibb CVR Exp. 12/31/2020
FOLD / Amicus Therapeutics, Inc.
HARP / Harpoon Therapeutics, Inc.
US74140Y1010 / Prevail Therapeutics Inc.
EXEL / Exelixis, Inc.
DRNA / Dicerna Pharmaceuticals Inc
FGEN / FibroGen, Inc. Call
BCEL / Atreca, Inc.
IRWD / Ironwood Pharmaceuticals, Inc.
IPHA / Innate Pharma S.A. - Depositary Receipt (Common Stock)
PIRS / Pieris Pharmaceuticals, Inc.
XOMA / XOMA Royalty Corporation
GMXAY / Genmab A/S
ZIOP / Alaunos Therapeutics Inc
US16706W1027 / Chiasma Inc
US33830X1046 / Five Prime Therapeutics Inc
RARE / Ultragenyx Pharmaceutical Inc.
FGEN / FibroGen, Inc.
UROV / Urovant Sciences Ltd
RGLS / Regulus Therapeutics Inc.
KURA / Kura Oncology, Inc.
IOVA / Iovance Biotherapeutics, Inc.
MRUS / Merus N.V.
EIGR / Eiger BioPharmaceuticals, Inc.
MGTX / MeiraGTx Holdings plc
IGMS / IGM Biosciences, Inc.
TRIL / Trillium Therapeutics Inc
SGMO / Sangamo Therapeutics, Inc.
TCRR / Tcr2 Therapeutics Inc
RCUS / Arcus Biosciences, Inc.
SAGE / Sage Therapeutics, Inc.
SVRA / Savara Inc.
ARGX / argenx SE - Depositary Receipt (Common Stock)
ASMB / Assembly Biosciences, Inc.
SELB / Selecta Biosciences Inc
DNLI / Denali Therapeutics Inc.
ACRS / Aclaris Therapeutics, Inc.
XFOR / X4 Pharmaceuticals, Inc.
ACAD / ACADIA Pharmaceuticals Inc.
VSTM / Verastem, Inc.
NLTX / Neoleukin Therapeutics, Inc.
CYCN / Cyclerion Therapeutics, Inc.
CTMX / CytomX Therapeutics, Inc.
SURF / Surface Oncology Inc
BPMC / Blueprint Medicines Corporation
ANAB / AnaptysBio, Inc.
MORF / Morphic Holding, Inc.
CRNX / Crinetics Pharmaceuticals, Inc.
FATE / Fate Therapeutics, Inc.
ARVN / Arvinas, Inc.
CRSP / CRISPR Therapeutics AG
IONS / Ionis Pharmaceuticals, Inc.
XNCR / Xencor, Inc.
MRTX / Mirati Therapeutics, Inc.